| 1 |
35170443 | The Relationship between albumin-Bilirubin grade and survival in hepatocelluler carcinoma patients treated with sorefanib. | 2022 Feb |
2 |
| 2 |
34052255 | Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. | 2021 Oct |
1 |
| 3 |
34155918 | Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance? | 2021 Sep |
2 |
| 4 |
34268947 | Efficacy of sorafenib combined with transcatheter hepatic arterial chemoembolization in treating intermediate-advanced hepatocellular carcinoma. | 2021 May-Jun |
1 |
| 5 |
34359658 | On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. | 2021 Jul 26 |
1 |
| 6 |
34434234 | Efficacy of Sorafenib Combined with Interventional Therapy on Primary Liver Cancer Patients and Its Effect on Serum AFP, VEGF, and GGT. | 2021 |
2 |
| 7 |
34583091 | Efficacy and safety of sorafenib plus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. | 2021 Dec |
2 |
| 8 |
34650031 | GP73-mediated secretion of AFP and GP73 promotes proliferation and metastasis of hepatocellular carcinoma cells. | 2021 Oct 14 |
1 |
| 9 |
32521890 | Sorafenib combined with transarterial chemoembolization prolongs survival of patients with advanced hepatocellular carcinoma. | 2020 Mar-Apr |
1 |
| 10 |
31467872 | Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. | 2019 |
1 |
| 11 |
31768344 | Systemic Treatment for Advanced Hepatocellular Carcinoma. | 2019 Oct |
1 |
| 12 |
31768351 | Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. | 2019 Oct |
1 |
| 13 |
28466374 | The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. | 2018 Apr |
1 |
| 14 |
29492203 | Protein biosynthesis, a target of sorafenib, interferes with the unfolded protein response (UPR) and ferroptosis in hepatocellular carcinoma cells. | 2018 Feb 2 |
2 |
| 15 |
29682199 | Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort. | 2018 Mar 30 |
2 |
| 16 |
29805623 | Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. | 2018 Jun |
5 |
| 17 |
29866075 | Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. | 2018 Jun 4 |
1 |
| 18 |
30215039 | Synergistic effect of metformin on sorafenib in in vitro study using hepatocellular carcinoma cell lines. | 2018 Aug |
1 |
| 19 |
27837395 | Evaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography. | 2017 Jan |
2 |
| 20 |
28261338 | Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis. | 2017 |
1 |
| 21 |
28633200 | Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review. | 2017 Dec |
1 |
| 22 |
26546044 | Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib. | 2016 Jan 28 |
9 |
| 23 |
26831408 | The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization. | 2016 Feb 2 |
3 |
| 24 |
27067685 | [Evaluation of Sorafenib for Hepatocellular Carcinoma with Low α-Fetoprotein by Arrival Time Parametric Imaging Using Contrast-Enhanced Ultrasonography with Sonazoid]. | 2016 Feb |
2 |
| 25 |
27308660 | Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma. | 2016 Jun |
1 |
| 26 |
27431630 | [Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib]. | 2016 Jul |
1 |
| 27 |
27732875 | Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. | 2016 Dec 1 |
1 |
| 28 |
27895433 | Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. | 2016 Nov 14 |
1 |
| 29 |
24836552 | Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. | 2015 May |
1 |
| 30 |
25649133 | Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib. | 2015 Feb 4 |
1 |
| 31 |
25861764 | Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. | 2015 Jun |
1 |
| 32 |
25870375 | A novel approach using sorafenib in alpha fetoprotein-producing hepatoid adenocarcinoma of the lung. | 2015 Apr |
2 |
| 33 |
25927582 | Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib. | 2015 Apr 28 |
2 |
| 34 |
26249525 | Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. | 2015 Oct |
1 |
| 35 |
26351418 | Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma. | 2015 May-Aug |
1 |
| 36 |
26421430 | Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. | 2015 |
1 |
| 37 |
27508193 | Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. | 2015 |
4 |
| 38 |
23608740 | Metastatic hepatocellular carcinoma: when surgery and successive palliative treatments lead to remission. | 2014 Feb |
1 |
| 39 |
24833103 | Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma. | 2014 Nov |
1 |
| 40 |
23347387 | Recent topics on α-fetoprotein. | 2013 Aug |
3 |
| 41 |
23395995 | Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. | 2013 Jun |
2 |
| 42 |
23578581 | Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study. | 2013 Sep |
1 |
| 43 |
21190093 | Hepatocellular carcinoma presenting as an incidental isolated malignant portal vein thrombosis. | 2012 Sep |
1 |
| 44 |
22176637 | Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice. | 2012 Apr |
1 |
| 45 |
22414760 | Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. | 2012 Jul |
4 |
| 46 |
22492703 | Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP. | 2012 Nov |
1 |
| 47 |
22890083 | Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. | 2012 |
3 |
| 48 |
23060390 | Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. | 2012 Oct |
3 |
| 49 |
21883324 | Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. | 2011 Oct |
1 |
| 50 |
21885876 | The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. | 2011 |
4 |